Matches in Wikidata for { <http://www.wikidata.org/entity/Q92354503> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q92354503 description "articolo scientifico (pubblicato il 2020)" @default.
- Q92354503 description "artikull shkencor i botuar më 01 shkurt 2020" @default.
- Q92354503 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q92354503 description "im Februar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92354503 description "scientific article published on 01 February 2020" @default.
- Q92354503 description "wetenschappelijk artikel" @default.
- Q92354503 description "наукова стаття, опублікована 1 лютого 2020" @default.
- Q92354503 name "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 name "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 type Item @default.
- Q92354503 label "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 label "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 prefLabel "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 prefLabel "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 P1433 Q92354503-CD837102-50E9-4BC8-B0BF-B3CA33B2D626 @default.
- Q92354503 P1476 Q92354503-91338946-3CF1-482E-AB2D-DEED5C3AAA12 @default.
- Q92354503 P2093 Q92354503-45FEF436-A2C0-4064-99FB-0AA90336735C @default.
- Q92354503 P2093 Q92354503-4C852AA9-283E-4136-99A3-BCB35D36CB85 @default.
- Q92354503 P2093 Q92354503-6A904806-8262-492C-BAD8-B6BA396C1165 @default.
- Q92354503 P2093 Q92354503-7796D3E4-49E7-4E67-B4D7-8C593D6B00E6 @default.
- Q92354503 P2093 Q92354503-BBE8E2C8-FF35-4F85-A744-90C08752044E @default.
- Q92354503 P2093 Q92354503-D1012CD3-4CE4-489C-A882-AD15D115CD96 @default.
- Q92354503 P304 Q92354503-12783EA8-9CFB-453D-A76E-A1807A95D52A @default.
- Q92354503 P31 Q92354503-EE1533CE-3FD9-4E4B-AAB0-925540C404D6 @default.
- Q92354503 P356 Q92354503-3ED88055-2BF6-4D5E-9DE3-589BEC5531B2 @default.
- Q92354503 P433 Q92354503-08294863-4ABA-47FD-B97B-99F3E0AEFC79 @default.
- Q92354503 P478 Q92354503-DBEFBA3C-DA80-4FC3-A33D-99E84B710520 @default.
- Q92354503 P577 Q92354503-9D1644FF-A6D5-4A97-9637-0399E95911A2 @default.
- Q92354503 P698 Q92354503-37159317-4CFD-481E-B76F-9FC4CB5978FB @default.
- Q92354503 P921 Q92354503-77FC3C31-EFE6-4947-BF25-33503CA70895 @default.
- Q92354503 P921 Q92354503-889BF6C0-A9D9-49CC-A6B6-188FE043A89C @default.
- Q92354503 P356 THY.2019.0202 @default.
- Q92354503 P698 31892283 @default.
- Q92354503 P1433 Q15709940 @default.
- Q92354503 P1476 "Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib" @default.
- Q92354503 P2093 "Antoine Italiano" @default.
- Q92354503 P2093 "Benjamin Bonhomme" @default.
- Q92354503 P2093 "Isabelle Soubeyran" @default.
- Q92354503 P2093 "Laura Leroy" @default.
- Q92354503 P2093 "Sylvestre Le Moulec" @default.
- Q92354503 P2093 "Yann Godbert" @default.
- Q92354503 P304 "343-344" @default.
- Q92354503 P31 Q13442814 @default.
- Q92354503 P356 "10.1089/THY.2019.0202" @default.
- Q92354503 P433 "2" @default.
- Q92354503 P478 "30" @default.
- Q92354503 P577 "2020-02-01T00:00:00Z" @default.
- Q92354503 P698 "31892283" @default.
- Q92354503 P921 Q18556131 @default.
- Q92354503 P921 Q19000862 @default.